Clinical Trial Update: Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the antifibrotic agent GI262570 in patients with chronic hepatitis C and liver cirrhosis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatitis C

Drugs mentioned

• GI262570

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cirrhosis, Liver | Phase 2 | Status: COMPLETED | Results posted: 2017-12-11